Fig. 6: MEG3 inhibits C-myc and CyclinD1 dependent on PKM2. | Cell Death & Disease

Fig. 6: MEG3 inhibits C-myc and CyclinD1 dependent on PKM2.

From: Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN

Fig. 6

A Co-immunoprecipitation (IP) with anti-PKM2 followed by Western blotting with Histone H3 in the Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively. IgG IP as negative control. INPUT refers to Western blotting with Histone H3. B Western blotting analysis with anti-pH3T11, anti- H3K9me3, anti-H3K9Ac in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, pCMV6-A-GFP-MEG3 plus pcDNA3-PKM2, respectively. β-actin as an internal control. C Chromatin immunoprecipitation (CHIP) with anti-H3K9Ac followed by PCR with C-Myc promoter and CyclinD1 promoter primers in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, respectively. IgG CHIP as negative control. C-Myc promoter and CyclinD1 promoter as INPUT. D Western blotting analysis with anti-C-myc, anti- cyclinD1 in liver cancer cells Hep3B cell lines transfected with pCMV6-A-GFP, pCMV6-A-GFP-MEG3, pCMV6-A-GFP-MEG3 plus pcDNA3-PKM2, respectively. β-actin as an internal control

Back to article page